GRCE

Grace Therapeutics, Inc. is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, and reduced side effects. Its lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. The nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. Its other pipeline includes GTX-102, which is targeted as the first potential therapy for the treatment of ataxia-telangiectasia (AT) in a pediatric population and GTx-101, which is a topical administration via a bioadhesive, film-forming polymer, for the treatment of pain associated with postherpetic neuralgia.

Wall Street analysts forecast GRCE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRCE is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Grace Therapeutics, Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Grace Therapeutics, Inc. EPS for the last quarter amounts to -0.06 USD, decreased -80.00 % YoY.

Grace Therapeutics, Inc (GRCE) has 0 emplpoyees as of December 17 2025.

Today GRCE has the market capitalization of 51.68M USD.